FDA approved Joenja (leniolisib) for Activated PI3K Delta Syndrome in Patients 12 and OlderFDA approved Joenja for Rare Immune Disorder in Patients 12 and Older

Joenja is a kinase inhibitor. It inhibits activated phosphoinositide 3-kinase delta (PI3Kδ).

Joenja is indicated for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS) in adult and pediatric patients 12 years of age and older. APDS is associated with genetic mutations in PIK3CD or PIK3R1. In the clinical trial, patients had nodal and/or extranodal lymphoproliferation and clinical findings compatible with APDS, such as a history of repeated oto-sino-pulmonary infections or organ dysfunction.

Verify pregnancy status in females of reproductive potential prior to initiating treatment. The recommended dosage is 70 mg administered orally twice daily approximately 12 hours apart, with or without food, in adult and pediatric patients 12 years of age and older weighing 45 kg or greater. There is no recommended dosage for patients weighing less than 45 kg. If a dose is missed by more than 6 hours, wait and take the next dose at the usual time. If vomiting occurs within 1 hour after taking Joenja, take Joenja as soon as possible. If vomiting occurs more than 1 hour after dosing, wait and take the next dose at the usual time.

The efficacy of Joenja was evaluated in the placebo-controlled portion of Study 2201 (NCT02435173), a 12-week blinded, randomized, placebo-controlled study in adult and pediatric patients 12 years of age and older with confirmed APDS-associated genetic PI3Kδ mutation. Thirty-one patients were randomized 2:1 to receive Joenja 70 mg (N=21) or placebo (N=10) twice daily for 12 weeks. The co-primary efficacy endpoints were improvement in lymphoproliferation, measured by change from baseline in lymphadenopathy using log10-transformed sum of product diameters, and normalization of immunophenotype, measured by percentage of naive B cells out of total B cells. Both co-primary efficacy endpoints were statistically significant. For the log10-transformed SPD of index lesions, the LS mean change from baseline was -0.27 (SE 0.04) for Joenja versus -0.02 (SE 0.05) for placebo, with a difference vs. placebo of -0.25 (95% CI -0.38, -0.12). Trial data for the second co-primary endpoint (normalization of immunophenotype) are not fully detailed in the label.

Verify pregnancy status in females of reproductive potential prior to initiating treatment. Contraindications are not reported in the label. Warnings and precautions are not detailed in the provided label text.

Joenja is the first FDA-approved medication for APDS. It offers a targeted oral therapy for patients 12 years and older weighing at least 45 kg. The label does not provide information on comparative efficacy or long-term outcomes. Clinical use should be guided by the confirmed genetic diagnosis and the patient's clinical status.